ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations

© 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd..

Allogeneic hematopoietic stem cell transplantations (HSCTs) represent a curative strategy for treating hematologic malignancies yet bear dangerous and frequently life-threatening complications including the development of graft-versus-host disease. Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow. During the course of his disease, the patient underwent consecutive allogeneic HSCTs, during which he developed a clinical meaningful and hitherto unreported ABO subgroup incompatibility, leading to persistent hemolysis. Testing for ABO subgroups during donor selection, especially after consecutive allogeneic HSCTs, may therefore aid to prevent these complications.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:2

Enthalten in:

EJHaem - 2(2021), 2 vom: 16. Mai, Seite 280-284

Sprache:

Englisch

Beteiligte Personen:

Hecker, Judith S [VerfasserIn]
Wahida, Adam [VerfasserIn]
Hameister, Erik [VerfasserIn]
Filo, Aneta [VerfasserIn]
Ruland, Jürgen [VerfasserIn]
Bassermann, Florian [VerfasserIn]
Hildebrandt, Martin [VerfasserIn]
Verbeek, Mareike [VerfasserIn]
Poeck, Hendrik [VerfasserIn]

Links:

Volltext

Themen:

A1/A2 subtyping of blood group A
ABO incompatibility
Allogeneic hematopoietic stem cell transplantation
Case Reports
Hemolysis

Anmerkungen:

Date Revised 19.07.2022

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

doi:

10.1002/jha2.190

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM343654997